公开(公告)号：EP1786443B1

公开(公告)日：2018-06-06

申请号：EP05773414.7

申请日：2005-07-19

申请人： Celator Pharmaceuticals, Inc. ,  The Trustees of Princeton University

发明人： MAYER, Lawrence, D. ,  PRUD'HOMME, Robert, K. ,  ALLEN, Christine, J. ,  SAAD, Walid, S.

IPC分类号： A61K31/74 ,  A61K31/77 ,  A61K8/85 ,  A61K9/51 ,  A61K45/06 ,  A61K47/55 ,  A61K47/58 ,  A61K47/59 ,  A61K47/60 ,  A61K47/69 ,  A61Q17/04 ,  B82Y5/00

CPC分类号： A61K47/6931 ,  A61K8/85 ,  A61K9/5153 ,  A61K45/06 ,  A61K47/22 ,  A61K47/54 ,  A61K47/543 ,  A61K47/545 ,  A61K47/55 ,  A61K47/551 ,  A61K47/552 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K2800/57 ,  A61Q17/04 ,  B82Y5/00

摘要： Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

公开(公告)号：EP1744764B1

公开(公告)日：2012-05-30

申请号：EP05738885.2

申请日：2005-04-22

申请人： Celator Pharmaceuticals, Inc.

发明人： MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

IPC分类号： A61K31/7068 ,  A61K31/704 ,  A61K31/706 ,  A61K9/127

CPC分类号： A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

摘要： Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

公开(公告)号：EP1443900B1

公开(公告)日：2012-05-23

申请号：EP02774210.5

申请日：2002-11-13

申请人： Celator Pharmaceuticals, Inc.

发明人： WEBB, Murray ,  TARDI, Paul ,  MAYER, Lawrence, D. ,  ICKENSTEIN, Ludger, M.

IPC分类号： A61K9/00

CPC分类号： A61K9/1271 ,  A61K9/127 ,  A61K9/1278

摘要： Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to an non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.

公开(公告)号：EP2222278A1

公开(公告)日：2010-09-01

申请号：EP08855240.1

申请日：2008-11-26

申请人： Celator Pharmaceuticals, Inc.

发明人： ANSELL, Steven, M. ,  JOHNSTONE, Sharon ,  TARDI, Paul ,  MAYER, Lawrence

IPC分类号： A61K9/127

CPC分类号： A61K9/1075 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/337 ,  A61K47/543 ,  C07D305/14

摘要： Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

公开(公告)号：EP1976485A2

公开(公告)日：2008-10-08

申请号：EP06846044.3

申请日：2006-12-22

申请人： Celator Pharmaceuticals, Inc.

发明人： DICKO, Awa ,  TARDI, Paul ,  MAYER, Lawrence ,  JOHNSTONE, Sharon

IPC分类号： A61K9/127

CPC分类号： A61K9/1278

摘要： Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

公开(公告)号：EP1817005A1

公开(公告)日：2007-08-15

申请号：EP05849544.1

申请日：2005-11-18

申请人： Celator Pharmaceuticals, Inc.

发明人： TARDI, Paul ,  WEBB, Murray ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  MAYER, Lawrence

IPC分类号： A61K9/127

CPC分类号： A61K9/127 ,  A61K9/1278

摘要： This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.

公开(公告)号：EP1617828A2

公开(公告)日：2006-01-25

申请号：EP04725252.3

申请日：2004-04-02

申请人： Celator Pharmaceuticals, Inc.

发明人： TARDI, Paul ,  HARASYM, Troy ,  WEBB, Murray ,  SHEW, Clifford

IPC分类号： A61K31/00

CPC分类号： A61K9/127 ,  A61K9/1075 ,  A61K9/51 ,  A61K45/06

摘要： Delivery vehicle compositions having stably associated therewith at least one therapeutic agent and at least one drug resistance modulator are useful in achieving a biologic effect to a drug resistance target.

公开(公告)号：EP3936153A1

公开(公告)日：2022-01-12

申请号：EP21182826.4

申请日：2017-01-11

申请人： Celator Pharmaceuticals, Inc.

发明人： DRUMMOND, Daryl C. ,  GENG, Bolin ,  KIRPOTIN, Dmitri B. ,  TIPPARAJU, Suresh K. ,  KOSHKARYEV, Alexander ,  ALKAN, Ozan

IPC分类号： A61K48/00 ,  A61K31/4745 ,  A61K31/7068 ,  A61K31/555 ,  A61K9/127 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/497 ,  C07D403/12 ,  A61P35/00

摘要： Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

公开(公告)号：EP3373919A1

公开(公告)日：2018-09-19

申请号：EP16865052.1

申请日：2016-11-10

申请人： Celator Pharmaceuticals, Inc. ,  Oregon Health & Science University

发明人： GORDON, Max ,  TARDI, Paul ,  TYNER, Jeffrey ,  MAYER, Lawrence

IPC分类号： A61K31/00 ,  A61P35/00 ,  A61P35/02 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  A61K9/127 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7068 ,  A61P35/02 ,  C12Q1/68 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

摘要： Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

公开(公告)号：EP2187869A4

公开(公告)日：2013-06-26

申请号：EP08871849

申请日：2008-08-14

申请人： CELATOR PHARMACEUTICALS INC

发明人： TARDI PAUL ,  JOHNSTONE SHARON ,  MAYER LAWRENCE

IPC分类号： A61K9/127

CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/555 ,  A61K33/24